Cargando…
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Recently, two studies using ipilimumab, an anti-CTLA-4 monoclonal antibody (mab) demonstrated improvements in overall survival in the treatment of advanced melanoma. These studies utilized two different schedules of treatment in different patient categories (first and second line of treatment). Howe...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262765/ https://www.ncbi.nlm.nih.gov/pubmed/22077981 http://dx.doi.org/10.1186/1479-5876-9-196 |